原发性膜性肾病血栓形成研究进展及血硒对血栓形成的影响

文华 张(承德医学院附属医院，中国)
桂才 胡(承德医学院附属医院，中国)

摘要

血栓是肾病综合征（Nephrotic syndrome，NS）患者常见的并发症之一，尤其是在原发性膜性肾病（Idiopathic membranousnephropathy，IMN）患者中。血栓的形成严重影响了疾病的预后。目前研究表明，血栓形成的机制是错综复杂的，血栓的形成与血液的状态，损伤的血管内皮细胞以及自身的免疫系统是紧密相关的。目前，常见的预防血栓的方法是预防性抗凝治疗，但是抗凝就会有出血风险。本身合并血栓患者的预后是不良的，如果在抗凝过程中发生出血，则会大幅度增加患者死亡风险。硒以硒蛋白的形式参与机体的许多生理过程，已有研究表明血硒与血栓的形成有密切联系，因此对于研究血硒与血栓的关系是十分必要的。论文针对血栓形成机制及血硒对血栓的影响作一综述。

关键词

原发性膜性肾病；血栓；血硒

参考

Yuan WM, Cheng GY, Li YS, et al. Diagnostic significance of

PLA2R and IgG4 in elderly patients with idiopathic membranous

nephropathy[J]. Med J Chin PLA, 2017,42(9): 810-814.

Couser WG.Primary Membranous Nephropathy [J].Clin J Am Soc

Nephrol,2017,12 (6):983-997.

陈晓静,禹程远,邸鹏飞,等.特发性膜性肾病心血管并发症的机制

研究的进展[J].心血管康复医学杂志,2023,32(1):48-51.

K e r l i n B A , Ay o o b R , S m o y e r W E . E p i d e m i o l o g y a n d

p a t h o p h y s i o l o g y o f n e p h r o t i c s y n d r o m e - a s s o c i a t e d

thromboembolic disease [J].Clin J Am Soc Nephrol,2012,7

(3):513-520.

Alawami M,Wimalasena S,Ghashi R,et al.Acute arterial

cardiovascular events risk in patients with primary membranous

nephropathy [J].Intern Med J,2019,49(7):855-858.

Lee T,Derebail VK,Kshirsagar AV,et al.Patients with primary

membranous nephropathy are at high risk of cardiovascular events

[J].Kidney Int,2016,89(5):1111-1118.

鲁春蕾,刘昌华.特发性膜性肾病并发静脉血栓栓塞症的研究进

展[J].中华肾病研究电子杂志,2020,9(5):220-223.

Mirrakhimov AE, Ali AM, Barbaryan A, et al. Primary nephrotic

syndrome in adults as a risk factor for pulmonary embolism: an upto date review of the literature[J]. Int J Nephrol, 2014(5): 916760.

Singhal R, Brimble KS. Thromboembolic complications in the

nephrotic syndrome: Pathophysiology and clinical management[J].

Thromb Res, 2006,118(3):397-407.

Tsai AW,Cushman M,Rosamond WD,et a1.Coagulation factom,

inflammation mgrkers,and venous thromboembolism:the longitu.

dinal investigation of thromboembolism etiology(LITE)[J].Ameri

can joumal of medicine,2015,13(8):636-642.

Kerlin BA, Ayoob R, Smoyer WE. Epidemiology and

pathophysiology of nephrotic syndrome-associated thromboembolic

disease[J].Clin J Am Soc Nephrol, 2012,7(3):513-520.

Mirrakhimov AE, Ali AM, Barbaryan A, et al. Primary nephrotic

syndrome in adults as a risk factor for pulmonary embolism: an upto date review of the literature[J]. Int J Nephrol,2014(7):916760.

Wygledowska G, Grygalewicz J, Matuszewska E. Natural

coagulation inhibitors; antithrombin Ⅲ, protein C, protein S in

children with hypercoagulation due to nephrotic syndrome[J].Med

Wieku Rozwoj, 2001,5(4):377-388.

Kanffmann RH,Vehkamp JJ,Van Tilburg NH,et a1.Acquired

antithrombin Ul deficiency and thrombosis in the nephrotic syn[J].

drome.Am j mek,1978,65(4):607.

胡杰,杨洁,孙脊峰.膜性肾病凝血紊乱机制及治疗进展[J].解放

军医学杂志,2019,44(3):266-270.

SINGHAL R, BRIMBLE KS. Thromboembolic complications in the

nephrotic syndrome: Pathophysiology and clinical management[J].

Thrombosis Research: An International Journal on Vascular

Obstruction, Hemorrhage and Hemostasis,2006,118(3):397-407.

KERLIN B A, AYOOB R, SMOYER W E. Epidemiology

and pathophysiology of nephrotic syndrome-associated

thromboembolic disease[J]. Clinical journal of the American

Society of Nephrology: CJASN,2012,7(3):513-520.

Hamano K, Iwano M, Akai Y, et al. Expression of glomerular

plasminogen activator inhibitor type 1 in glomerulonephritis[J].Am

J Kidney Dis,2002,39(4):695-705.

Wakui H, Imai H, Komatsuda A, et al. Circulating antibodies

against alpha-enolase in patients with primary membranous

nephropathy (MN)[J].Clin Exp Immunol,1999,118(3):445-450.

López-Alemany R, Longstaff C, Hawley S, et al. Inhibition of cell

surface mediated plasminogen activation by a monoclonal antibody

against alpha-Enolase[J].Am J Hematol,2003,72(4):234-242.

Barbour SJ, Greenwald A, Djurdjev O, et al. Disease-specific

risk of venous thromboembolic events is increased in idiopathic

glomerulonephritis[J].Kidney Int. 2012,81(2):190-195.

Eneman B, Levtchenko E, van den Heuvel B, et al. Platelet

abnormalities in nephrotic syndrome[J].Pediatr Nephrol,

,31(8):1267-1279.

Eneman B, Elmonem MA, van den Heuvel LP, et al. Pituitary

adenylate cyclase-activating polypeptide (PACAP) in zebrafish

models of nephrotic syndrome[J].PLoS One,2017,12(7):0182100.

Gao C, Xie R, Yu C, et al. Procoagulant activity of erythrocytes and

platelets through phosphatidylserine exposure and microparticles

release in patients with nephrotic syndrome[J].ThrombHaemo

st,2012,107(4):681-689.

Wang GH, Lu J, Ma KL,et al. The Release of MonocyteDerived Tissue Factor-Positive Microparticles Contributes to aHypercoagulable State in Idiopathic Membranous Nephropathy[J].

Atheroscler Thromb,2019,26(6):538-546.

Rosas M, Slatter DA, Obaji SG, et al. The procoagulant activity of

tissue factor expressed on fibroblasts is increased by tissue factornegative extracellular vesicles[J].PLoS One,2020,15(10):e0240189.

Abid Hussein MN, Böing AN, Biró E, et al. Phospholipid

composition of in vitro endothelial microparticles and their in vivo

thrombogenic properties[J]. Thromb Res, 2008,121(6):865-871.

Aras O, Shet A, Bach RR,et al. Induction of microparticle- and

cell-associated intravascular tissue factor in human endotoxemia[J].

Blood,2004,103(12):4545-4553.

Chironi GN, Boulanger CM, Simon A, et al. Endothelial

microparticles in diseases[J].Cell Tissue Res,2009,335(1):143-151.

Combes V, Simon AC, Grau GE, et al. In vitro generation of

endothelial microparticles and possible prothrombotic activity

in patients with lupus anticoagulant[J].Clin Invest,1999,104(1):

-102.

Shet AS, Aras O, Gupta K,et al. Sickle blood contains tissue

factor-positive microparticles derived from endothelial cells and

monocytes[J].Blood,2003,102(7):2678-2683.

Roca N, Jatem E, Martín ML, et al. Relationship between

soluble urokinase-type plasminogen activator receptor and serum

biomarkers of endothelial activation in patients with idiopathic

nephrotic syndrome[J].Clin Kidney J,2020,14(2):543-549.

Sabatier F, Roux V, Anfosso F, et al. Interaction of endothelial

microparticles with monocytic cells in vitro induces tissue factordependent procoagulant activity[J].Blood,2002,99(11):3962-3970.

Tkaczyk M, Czupryniak A, Owczarek D, et al. Markers of

endothelial dysfunction in children with idiopathic nephrotic

syndrome[J].AmJNephrol,2008,28(2):197-202.

Zaffanello M, Brugnara M, Fanos V,et al. Prophylaxis with AT III

for thromboembolism in nephrotic syndrome: why should it be

done[J].Urol Nephrol,2009,41(3):713-716.

王姣姣.特发性膜性肾病静脉血栓形成机制的研究进展[J].临床

与病理杂志,2022,42(9):2301-2306.

Chen X, Geng X, Jin S, et al. The Association of Syndecan-1,

Hypercoagulable State and Thrombosis and in Patients

With Nephrotic Syndrome[J].Clin Appl Thromb Hemost,

(27):10760296211010256.

Nickolas TL, Radhakrishnan J, Appel GB. Hyperlipidemia

and thrombotic complications in patients with membranous

nephropathy[J].Semin Nephrol,2003,23(4):406-411.

Resh M, Mahmoodi BK, Navis GJ, et al. Statin use in patients

with nephrotic syndrome is associated with a lower risk of venous

thromboembolism[J].Thromb Res,2011,127(5):395-399.

Orsi FA, Cannegieter SC, Lijfering WM. Statin Therapy to Revert

Hypercoagulability and Prevent Venous Thromboembolism: A

Narrative Review[J].Semin Thromb Hemost,2019,45(8):825-833.

Cremoni M, Brglez V, Perez S,et al. Th17-Immune Response

in Patients With Membranous Nephropathy Is Associated With

Thrombosis and Relapses[J].Front Immunol,2020(11):574997.

Xu X, Wang G, Chen N,et al. Long-Term Exposure to Air Pollution

and Increased Risk of Membranous Nephropathy in China[J].Am

Soc Nephrol,2016,27(12):3739-3746.

Liu W, Gao C, Dai H, et al. Immunological Pathogenesis of

Membranous Nephropathy: Focus on PLA2R1 and Its Role[J].

Front Immunol,2019(10):1809.

Xu X, Nie S, Ding H, et al. Environmental pollution and kidney

diseases[J].Nat Rev Nephrol,2018,14(5):313-324.

Van de Logt AE, Fresquet M, Wetzels JF,et al. The anti-PLA2R

antibody in membranous nephropathy: what we know and what

remains a decade after its discovery[J].Kidney Int,2019,96(6):1292-

Nagashima R, Maeda K, Yuda F,et al. Helicobacter pylori antigen

in the glomeruli of patients with membranous nephropathy[J].

Virchows Arch,1997 ,431(4):235-239.

Yang AH, Lin BS, Kuo KL,et al. The clinicopathological

implications of endothelial tubuloreticular inclusions found in

glomeruli having histopathology of idiopathic membranous

nephropathy[J].Nephrol Dial Transplant,2009,24(11):3419-3425.

Xie J, Liu L, Mladkova N,et al. The genetic architecture of

membranous nephropathy and its potential to improve non-invasive

diagnosis[J].Nat Commun,2020,11(1):1600.

Motavalli R, Etemadi J, Kahroba H,et al. Immune system-mediated

cellular and molecular mechanisms in idiopathic membranous

nephropathy pathogenesis and possible therapeutic targets[J].Life

Sci,2019(238):116923.

Setiawan B, Rosalina R, Pangarsa EA, et al. Clinical Evaluation for

the Role of High-Sensitivity C-Reactive Protein in Combination

with D-Dimer and Wells Score Probability Test to Predict the

Incidence of Deep Vein Thrombosis Among Cancer Patients[J].Int

J Gen Med,2020(13):587-594.

Pereira Wde F, Brito-Melo GE, Guimarães FT,et al. The role of

the immune system in idiopathic nephrotic syndrome: a review of

clinical and experimental studies[J].Inflamm Res,2014,63(1):1-12.

Maugeri N, Capobianco A, Rovere-Querini P, et al. Platelet

microparticles sustain autophagy-associated activation of

neutrophils in systemic sclerosis[J].Sci Transl Med, 2018,10

(451):eaao3089.

Park SY, Lee SW, Kim HY, et al. HMGB1 induces angiogenesis in

rheumatoid arthritis via HIF-1α activation[J].Eur J Immunol,2015,

(4):1216-1227.

Wu H, Li R, Pei LG,et al. Emerging Role of High Mobility

Group Box-1 in Thrombosis-Related Diseases[J].Cell Physiol

Biochem,2018,47(4):1319-1337.

Ahrens I, Chen YC, Topcic D,et al. HMGB1 binds to activated

platelets via the receptor for advanced glycation end products

and is present in platelet rich human coronary artery thrombi[J].

Thromb Haemost,2015,114(5):994-1003.

Chen G, Liu H, Liu F. A glimpse of the glomerular milieu: from

endothelial cell to thrombotic disease in nephrotic syndrome[J].

Microvasc Res,2013(89):1-6.

Llach F. Hypercoagulability, renal vein thrombosis, and other

thrombotic complications of nephrotic syndrome[J].Kidney

Int,1985,28(3):429-439.

Henry BM, Vikse J, Benoit S,et al. Hyperinflammation

and derangement of renin-angiotensin-aldosterone system

in COVID-19: A novel hypothesis for clinically suspected

hypercoagulopathy and microvascular immunothrombosis[J].Clin

Chim Acta,2020(507):167-173.

Rittirsch D, Flierl MA, Nadeau BA,et al. Functional roles for C5a

receptors in sepsis[J].Nat Med,2008,14(5):551-557.

Macé C, Chugh SS. Nephrotic syndrome: components,

connections, and angiopoietin-like 4-related therapeutics[J].Am

Soc Nephrol,2014,25(11):2393-2398.

Noubouossie DF, Reeves BN, Strahl BD, et al. Neutrophils: back

in the thrombosis spotlight[J].Blood,2019,133(20):2186-2197.

Papp LV, Lu J, Holmgren A, et al. From selenium to selenoproteins:

synthesis, identity, and their role in human health[J].Antioxid

Redox Signal,2007,9(7):775-806.

钟国清,张志朋.有机硒的合成及其在养殖中的应用[J].饲料工

业,2009,30(16):29-31.

邵黎雄,陆建梅,姜雪峰.硒,人类不可或缺的元素[J].自然杂志,

,41(6):453-459.

Schweizer U, Fradejas-Villar N. Why 21? The significance of

selenoproteins for human health revealed by inborn errors of

metabolism[J].FASEB J,2016,30(11):3669-3681.

陈勤,徐光禄,薛文岚,等.补硒对低硒大鼠血小板血栓素A_2

聚集性和5-羟色胺释放的影响[J].西安医科大学学报(中文

版),1996(1):31-34.

化罗明,徐光禄,谭武红,等.补硒对克山病病区居民血浆和血小板

血栓素的影响[J].地方病通报,1997(1):1-3.

瞿祥虎,黄开勋,徐辉碧.硒和维生素E对前列环素和血栓素合成

的调控机制[J].微量元素与健康研究,1999(2):5-8.

李萍,弥曼,杜洪霞,等.亚硒酸钠对糖尿病大鼠血小板聚集功能的

影响[J].南方医科大学学报,2010,30(1):193-194.

Pan T, Hu X, Liu T, et al. MiR-128-1-5p regulates tight

junction induced by selenium deficiency via targeting cell

adhesion molecule 1 in broilers vein endothelial cells[J].Cell

Physiol,2018,233(11):8802-8814.

Cao C, Fan R, Zhao J, et al. Impact of exudative diathesis

induced by selenium deficiency on LncRNAs and their roles in

the oxidative reduction process in broiler chick veins[J].Oncotarg

et,2017,8(13):20695-20705.

Du Q, Yao H, Yao L,et al. Selenium Deficiency Influences the

Expression of Selenoproteins and Inflammatory Cytokines in

Chicken Aorta Vessels[J].Biol Trace Elem Res,2016,173(2):

-513.

郭晓玲,马国珍,张美兰.溶栓疗法对急性心肌梗死患者血清中铁

锌铜锰硒含量变化的研究[J].中国医师杂志,2002(S1):38-40.

Zheng Z, Liu L, Zhou K ,et al.Anti-Oxidant and Anti-Endothelial

Dysfunctional Properties of Nano-Selenium in vitro and in

vivo of Hyperhomocysteinemic Rats[J].International Journal of

Nanomedicine, 2020(15):4501-4521.

Zhu ML, Wang G, Wang H,et al. Amorphous nano-selenium

quantum dots improve endothelial dysfunction in rats and prevent

atherosclerosis in mice through Na+/H+ exchanger 1 inhibition[J].

Vascul Pharmacol,2019(115):26-32.

刘红梅,黄开勋,杨劲松,等.氧化固醇对不同硒状态大鼠前列环素

和内皮素的影响[J].营养学报,2002,24(1):70-74.

张勇胜,李仁兰,刘妍,等.硒对人体健康作用的研究进展[J].内

科,2018,13(4):623-625+662.

王艳梅.硒对自身免疫性甲状腺炎自身抗体的影响[J].世界最新

医学信息文摘(连续型电子期刊),2018,18(23):111.

袁家林,石元刚.复合微量营养素对高脂血症大鼠血浆PGI2、

TXA2水平的影响[J].第三军医大学学报,2003,25(2):141-143.

陈利明,杨红兵,苑留云,等.富硒灵芝对动脉粥样硬化大鼠血脂代

谢及内皮细胞损伤的影响[J].河北中医药学报,2012,27(1):10-11.

李萍.阿斯匹林和硒对血液流变性、血小板功能及血栓形成的

作用及其联合作用[D].西安:西安交通大学,2002.

Nève J. Selenium as a risk factor for cardiovascular diseases[J].

Cardiovasc Risk,1996,3(1):42-47.

刘孟宇,李勇,高晓昕.硒的特性与心血管疾病的关系[J].中国临

床营养杂志,2003,11(4):295-297.

DOI: http://dx.doi.org/10.12345/yzlcyxzz.v7i2.16350